DIVISLAB \u2014 Recent Activity

Divi's Laboratories Ltd (BOM:532488) Q3 2026 Earnings Call Highlights: Strong Export ...

Divi's Laboratories Ltd reports a rise in total income and robust export sales, while navigating competitive pressures in the generics market and strategic capacity utilization.

Click to open →

Indian contract drug maker Divi's misses profit view on high material costs, one-off labour charge

Feb 11 (Reuters) - Indian contract drug manufacturer Divi's Laboratories reported third-quarter profit below estimates on Wednesday, as high raw material costs and a one-off charge due to changes in

Click to open →

Divi's Laboratories Ltd (BOM:532488) Q2 2026 Earnings Call Highlights: Strong Revenue Growth ...

Divi's Laboratories Ltd (BOM:532488) reports a 17% increase in total income and strategic shifts towards custom synthesis amid ongoing pricing pressures in the generics segment.

Click to open →

Indian drugmaker Divi's beats profit view for second quarter on API boost

(Reuters) -Indian drugmaker Divi's Laboratories reported second-quarter profit above analysts' estimates on Friday, helped by its business that focuses on customised production of chemical compounds

Click to open →

What To Expect From Divi's Laboratories Ltd (NSE:DIVISLAB) Q2 2026 Earnings

This article first appeared on GuruFocus. Divi's Laboratories Ltd (NSE:DIVISLAB) is set to release its Q2 2026 earnings on Nov 7, 2025. The consensus estimate for Q2 2026 revenue is $25.86 billion, and the earnings are expected to come in at $22.90 per share.

Click to open →

All bark, no bite: Trump’s latest trade war turns into another TACO salad for Wall Street

Markets actually improved on the latest surprise round of Trump tariffs.

Click to open →

Indian drugmaker Divi's misses June-quarter profit view on weak US pricing

The Hyderabad-based company's consolidated net profit rose 26.7% to 5.45 billion rupees ($62 million) for the quarter ended June 30. Indian generic drugmakers, which get a significant chunk of their revenue from the U.S., have been grappling with weak pricing amid stiff competition in the region. Divi's, one of India's largest manufacturers of active pharmaceutical ingredients (API), has flagged pricing pressure and high competition in its generics business in global markets, adding that it ai

Click to open →

Divi's Laboratories Ltd (BOM:532488) Q4 2025 Earnings Call Highlights: Strong Financial ...

Divi's Laboratories Ltd (BOM:532488) reports robust growth in income and profit, while navigating supply chain constraints and competitive pressures.

Click to open →